Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04930055 · ClinicalTrials.gov registry record
Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)
A clinical trial, sponsored by Indiana University.
- Terminated
- Registry status
- 2,206
- Enrollment target
NCT04930055: Clinical Trial study, sponsored by Indiana University.
NCT04930055 is a clinical trial that was terminated before completion, run by Indiana University. The registered enrollment target is 2,206 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04930055 was terminated before completion, sponsored by Indiana University.
- TERMINATED
- Registry status
- 2,206 participants
- Enrollment target
Study Summary
The goals of this study are to assess initial or booster vaccine performance (safety and efficacy) and to collect serum and peripheral blood mononuclear cells (PBMCs) pre and post-vaccination to assess immune and other response parameters following immunization in cancer patients receiving either the Pfizer (BTN162b2), Moderna (mRNA-1273), or the Janssen (Ad26.COV2.S) vaccines.
Interventions
- BIOLOGICAL COVID-19 Vaccination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,206 participants |
| Start Date | 2021-06-30 |
| Est. Completion | 2022-03-08 |
Why NCT04930055 stopped before completion
NCT04930055 is an observational study that tracks outcomes without assigning an intervention. Its 2,206 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which COVID-19 Vaccination is the first listed.
NCT04930055 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04930055 about?
NCT04930055 is a clinical study titled "Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC)". The goals of this study are to assess initial or booster vaccine performance (safety and efficacy) and to collect serum and peripheral blood mononuclear cells (PBMCs) pre and post-vaccination to assess immune and other response parameters following immunization in cancer patients receiving either th...
What is the current status of trial NCT04930055?
This trial is currently terminated. The enrollment target is 2,206 participants. The study started on 2021-06-30. Estimated completion is 2022-03-08.
What interventions are being tested in trial NCT04930055?
The interventions under investigation include: COVID-19 Vaccination (BIOLOGICAL).
Who is sponsoring clinical trial NCT04930055?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05654207 · 2,200 participants · NA
WeCare: A System of Care for Black Youth
- NCT06144554 · 2,200 participants
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
- NCT06526988 · 2,200 participants · NA
Implementation and Interaction of Clinician And Patient-facing Tools Aiming to Intensify Neurohormonal Medicines for Heart Failure
- NCT06682650 · 2,200 participants · NA
Implementation of a ColoRectal Cancer Screening Tool in US Primary Care Practices - Usual Quality Improvement (10 Clinics) vs Normalization Process Theory-Participatory Learning in Action (10 Clinics)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI